On Monday, Shares of Sealed Air Corp (NYSE:SEE), subtract -0.30% and closed at $46.63 in the last trading session. The last trading range of the stock ranges between $46.30 and $47.80. Sealed Air Corporation (SEE) recently declared the launch of its StealthWrap™ ultra durable cartoning solution, a patented micro-layer, opaque cartoning alternative which allows primary package cartons to be protected for transit without the need for outer boxes or additional packaging materials.
The company also declared that XPO Logistics (XPO), a leading global provider of transportation and supply chain solutions, will be the first to bring this innovative packaging solution to market in the logistics industry. XPO is deploying StealthWrap™ in several distribution centers where it fulfills and ships e-commerce orders for customers.
StealthWrap™ is an exclusively engineered packaging product that provides security and protection while eliminating the need for extra shipping cartons and packing materials. When applied, StealthWrap™ shrinks and adheres to the dimensions of the product, obscures any markings or identification of the product inside, and provides a strong, damage-resistant covering.
Capital One Financial Corp. (NYSE:COF), jumped 3.42% and closed at $83.76 in the last trading session. The last trading range of the stock ranges between $80.95 and $83.82. The company’s Market capitalization is $41.29 Billion with the total Outstanding Shares of 489.22 million. Capital One Financial Corporation (COF) recently declared a quarterly dividend of $0.40 per share payable November 25, 2016 to stockholders of record as of November 14, 2016. The company has declared dividends on its common stock every quarter since it became an independent company on February 28, 1995. Dividends declared by the company are eligible for direct reinvestment in the company’s common stock under its Dividend Reinvestment and Stock Purchase Plan. For additional Plan information, stockholders should contact Computershare Trust Company, N.A., at 1-888-985-2057 (inside the U.S. and Canada) or 1-781-575-2725 (outside the U.S. and Canada).
The company also declared a quarterly dividend on the outstanding shares of its 6.00 percent Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”). Each outstanding share of the Series B Preferred Stock is represented by depositary shares, each representing a 1/40th interest in a share of Series B Preferred Stock. The dividend of $15.00 per share (equivalent to $0.375 per outstanding depositary share) will be paid on December 1, 2016 to stockholders of record at the close of business on November 16, 2016.
Endo International plc – Ordinary Shares (NASDAQ:ENDP), gained 3.47% and closed at $18.19 in the last trading session. The last trading range of the stock ranges between $17.65 and $18.63. Company stock’s 52-week range is $12.56 – $63.71 Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Branded Pharmaceuticals segment offers chronic pain administration products, such as BELBUCA, OPANA ER, and Percocet; Lidoderm for opioid analgesics; and Voltaren gel for osteoarthritis pain, in addition to XIAFLEX for treating Peyronies and Dupuytrens contracture diseases. This segment also provides Supprelin LA for central precocious puberty treatment; testosterone replacement therapies, such as Aveed and TESTOPEL, in addition to Fortesta and Testim gels; Frova and Sumavel DosePro for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; and Vantas for the palliative treatment of prostate cancer. The companys U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain administration, urology, central nervous system disorders, immunosuppression, oncology, womens health, and cardiovascular disease markets. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, counting attention deficit hyperactivity disorder, pain, womens health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, in addition to for government healthcare programs.